BPMC — Blueprint Medicines Share Price
0.000.00%
Last trade - 00:00- $5.66bn
- $5.43bn
- $508.82m
- 37
- 14
- 47
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 18.95 | ||
| Price to Tang. Book | 18.95 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.17% | ||
| Return on Equity | -31.26% | ||
| Operating Margin | -7.54% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 793.74 | 180.08 | 204.04 | 249.38 | 508.82 | 722.57 | 954.2 | 50.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Directors
- Jeffrey Albers CHM (49)
- Michael Landsittel CFO (49)
- Fouad Namouni CEX (52)
- Kathryn Haviland COO (45)
- Debra Durso-Bumpus CHO (51)
- Anthony Boral EVP (58)
- Philina Lee SVP
- Christopher Murray SVP (58)
- Percy Carter CSO (51)
- Tracey McCain CCO (53)
- Ariel Hurley VPR (47)
- Becker Hewes OTH (55)
- Christina Rossi OTH (45)
- Lynn Seely LED (62)
- Daniella Beckman DRC (42)
- Alexis Borisy IND (49)
- Lonnel Coats IND (56)
- George Demetri IND (64)
- Mark Goldberg IND (67)
- Nicholas Lydon IND (64)
- Charles Rowland IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 14th, 2008
- Public Since
- April 30th, 2015
- No. of Shareholders
- 7
- No. of Employees
- 649
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 64,575,904
- Address
- 45 Sidney Street, CAMBRIDGE, 02139
- Web
- https://www.blueprintmedicines.com/
- Phone
- +1 6173747580
- Contact
- Jenna Cohen
- Auditors
- Ernst & Young LLP
Upcoming Events for BPMC
Q1 2025 Blueprint Medicines Corp Earnings Release
Blueprint Medicines Corp Annual Shareholders Meeting
Blueprint Medicines Corp Annual Shareholders Meeting
Q2 2025 Blueprint Medicines Corp Earnings Release
Similar to BPMC
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Blueprint Medicines share price?
As of Today at 19:38 UTC, shares in Blueprint Medicines are trading at $87.66. This share price information is delayed by 15 minutes.
How has the Blueprint Medicines share price performed this year?
Shares in Blueprint Medicines last closed at $87.66 and the price had moved by -3.38% over the past 365 days. In terms of relative price strength the Blueprint Medicines share price has underperformed the S&P500 Index by -10.82% over the past year.
What are the analyst and broker recommendations for Blueprint Medicines?
The overall consensus recommendation for Blueprint Medicines is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Blueprint Medicines dividend yield?
Blueprint Medicines does not currently pay a dividend.
Does Blueprint Medicines pay a dividend?
Blueprint Medicines does not currently pay a dividend.
When does Blueprint Medicines next pay dividends?
Blueprint Medicines does not currently pay a dividend.
How do I buy Blueprint Medicines shares?
To buy shares in Blueprint Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Blueprint Medicines?
As of the previous close price of $87.66, shares in Blueprint Medicines had a market capitalisation of $5.66bn.
Where are Blueprint Medicines shares listed?
Here are the trading details for Blueprint Medicines:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BPMC
What kind of share is Blueprint Medicines?
Based on an overall assessment of its quality, value and momentum Blueprint Medicines is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Blueprint Medicines share price forecast for 2025?
The analyst consensus target price for shares in Blueprint Medicines is $126.00. That is 43.74% above the last closing price of $87.66.
Analysts covering Blueprint Medicines currently have a consensus Earnings Per Share (EPS) forecast of -$1.17 for the next financial year.
Find out moreWhat is the trend in the Blueprint Medicines share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Blueprint Medicines. Over the past six months, its share price has outperformed the S&P500 Index by +12.03%.
As of the last closing price of $87.66, shares in Blueprint Medicines were trading -7.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Blueprint Medicines PE Ratio?
The Blueprint Medicines PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $87.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Blueprint Medicines?
Blueprint Medicines' management team is headed by:
- Jeffrey Albers - CHM
- Michael Landsittel - CFO
- Fouad Namouni - CEX
- Kathryn Haviland - COO
- Debra Durso-Bumpus - CHO
- Anthony Boral - EVP
- Philina Lee - SVP
- Christopher Murray - SVP
- Percy Carter - CSO
- Tracey McCain - CCO
- Ariel Hurley - VPR
- Becker Hewes - OTH
- Christina Rossi - OTH
- Lynn Seely - LED
- Daniella Beckman - DRC
- Alexis Borisy - IND
- Lonnel Coats - IND
- George Demetri - IND
- Mark Goldberg - IND
- Nicholas Lydon - IND
- Charles Rowland - IND